<p><strong>Elderly Or Hepatically Impaired Patients</strong>: Elderly patients and those with hepatic impairment have been observed to have a decreased clearance of fluvoxamine maleate. Consequently, it may be appropriate to modify the initial dose and the subsequent dose titration for these patient groups.<br />
<br />
<strong>Pregnant Women During The Third Trimester</strong>: Neonates exposed to Fluvoxamine Maleate Tablets and other SSRIs or SNRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and&nbsp;tube feeding&nbsp;and may be at risk for persistent&nbsp;pulmonary hypertension&nbsp;of the newborn (PPHN). When treating pregnant women with Fluvoxamine Maleate Tablets during the third trimester, the physician should carefully consider the potential risks and benefits of treatment.</p>